B
Bull
Bull · 25%MTSR
$41.40
Scenario price
$70.500
-0.247 (-0.35%)At close
Loading chart…
- High
- 70.780
- Open
- 70.740
- VWAP
- 70.47
- Vol
- 27.91M
- Mkt Cap
- —
- Low
- 70.130
- Amount
- 1.97B
- EV/EBITDA, TTM
- -8.94
Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.
Valuation Metrics
The current forward P/E ratio for Metsera Inc (MTSR) is -8.88, compared to its 5-year average forward P/E of -10.50.
Alphio AI Price Scenarios for MTSR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MTSR
Events Timeline
News
8.502-18stocktwitsCormorant Increases MoonLake Stake Above 6%
7.012-16BenzingaPfizer Anticipates Slower Growth in 2026 Despite Efforts to Enhance Pipeline and Reduce Costs
2.011-21TipRanksNovo Nordisk Shares Face Challenges as Competitor Eli Lilly Enters the $1 Trillion Market Valuation Club
8.511-14BenzingaMarket Update: Warner Bros., Bill.com, C3 AI—Significant Auctions and Acquisitions Impact the Industry
5.011-14BenzingaNovo Nordisk, the Manufacturer of Ozempic, Encounters Board Restructuring
MTSR FAQ — answered by Alphio AI
Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. It operates in the Healthcare sector.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.